(Q36654727)

15 August 2017

1 reference

title

A role for transcription factor NF-kappaB in autoimmunity: possible interactions of genes, sex, and the immune response (English)

1 reference

15 August 2017

1 reference

Elizabeth Dale

1

1 reference

PubMed ID

17108242

15 August 2017

Miriam Davis

series ordinal

2

1 reference

PubMed ID

17108242

15 August 2017

Denise L Faustman

series ordinal

3

1 reference

15 August 2017

1 December 2006

1 reference

Advances in Physiology Education

15 August 2017

1 reference

15 August 2017

30

1 reference

15 August 2017

4

1 reference

15 August 2017

152-158

1 reference

NODing Off and Ramping Up

15 August 2017

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

NF-kappa B: ten years after

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Age and sex associations of 40 autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

NOD2 and Crohn's disease: loss or gain of function?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Role of cytokines in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Glucocorticoid Ligands Specify Different Interactions with NF-κB by Allosteric Effects on the Glucocorticoid Receptor DNA Binding Domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Essential role of human leukocyte antigen-encoded proteasome subunits in NF-kappaB activation and prevention of tumor necrosis factor-alpha-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

NOD mice are defective in proteasome production and activation of NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Negative interaction between the RelA(p65) subunit of NF-kappaB and the progesterone receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Increased CD8+ T cell apoptosis in scleroderma is associated with low levels of NF-kappa B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Biological agents for rheumatoid arthritis: targeting both physical function and structural damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Immunoproteasome subunit LMP2 expression is deregulated in Sjogren's syndrome but not in other autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Cotranslational biogenesis of NF-kappaB p50 by the 26S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Functional interaction of CARD15/NOD2 and Crohn's disease-associated TNFalpha polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Regulated commitment of TNF receptor signaling: a molecular switch for death or activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Long term safety of infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

NF-κB p105 Processing via the Ubiquitin-Proteasome Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

NF-kappa B hyperactivation has differential effects on the APC function of nonobese diabetic mouse macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Onset of multiple sclerosis associated with anti-TNF therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Etanercept-induced systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Effect of 17beta-estradiol on tumor necrosis factor-alpha-induced cytotoxicity in the human peripheral T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

The Met-196 -> Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Psoriasiform eruption induced by infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Sex differences in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-kappa B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

Induction of apoptosis in mature T cells by tumour necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FADVAN.00065.2006

21 January 2018

Identifiers

DOI

10.1152/ADVAN.00065.2006

1 reference

15 August 2017

1 reference

PubMed ID

17108242